Ascletis Pharma Stock Current Valuation
| ASCLF Stock | USD 1.04 0.12 13.04% |
Valuation analysis of Ascletis Pharma helps investors to measure Ascletis Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Ascletis Pharma's price fluctuation is out of control at this time. Calculation of the real value of Ascletis Pharma is based on 3 months time horizon. Increasing Ascletis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ascletis pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Ascletis Pharma. Since Ascletis Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ascletis Pink Sheet. However, Ascletis Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.04 | Real 1.06 | Hype 1.04 | Naive 0.98 |
The real value of Ascletis Pink Sheet, also known as its intrinsic value, is the underlying worth of Ascletis Pharma Company, which is reflected in its stock price. It is based on Ascletis Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ascletis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ascletis Pharma helps investors to forecast how Ascletis pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ascletis Pharma more accurately as focusing exclusively on Ascletis Pharma's fundamentals will not take into account other important factors: Ascletis Pharma Company Current Valuation Analysis
Ascletis Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ascletis Pharma Current Valuation | 116.15 M |
Most of Ascletis Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascletis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ascletis Pharma has a Current Valuation of 116.15 M. This is 99.19% lower than that of the Healthcare sector and 97.5% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.3% higher than that of the company.
Ascletis Pharma is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 125.39 Million. Ascletis Pharma totals roughly 116.15 Million in current valuation claiming about 93% of stocks in Biotechnology industry.Ascletis Fundamentals
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Shares Owned By Insiders | 67.02 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X | |||
| Revenue | 76.88 M | |||
| Gross Profit | 39.17 M | |||
| EBITDA | (169.35 M) | |||
| Net Income | (199.02 M) | |||
| Cash And Equivalents | 2.5 B | |||
| Cash Per Share | 2.28 X | |||
| Total Debt | 2.75 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 28.93 X | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (146.93 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 315 | |||
| Beta | 0.81 | |||
| Market Capitalization | 672.93 M | |||
| Total Asset | 2.83 B | |||
| Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.